President Donald Trump announced a new round of drug pricing agreements Monday afternoon at the White House, advancing his administration's push to make healthcare more affordable for Americans.

The deals involve companies including Bayer, Takeda, CSL, and several mid-size biotechs. They commit to most-favored-nation pricing that aligns U.S. prices with those paid in other developed countries. Participants will also offer lower prices for federal health programs and sell select medicines directly to patients via the TrumpRx platform in exchange for tariff relief.

The event began at 3 p.m. ET. It builds on earlier administration actions that have already produced measurable results. Prescription drug prices fell 0.8 percent in July and 3.1 percent over the prior year, marking the steepest annual decline in more than six decades.

TrumpRx, launched in February, has generated $700 million in patient savings. It provides direct discounts on hundreds of medications, including GLP-1 drugs now available as low as $149 per month, fertility treatments, insulin, and inhalers with cuts of 50 to 90 percent or more.

These steps follow the expiration of expanded Affordable Care Act subsidies at the end of last year, which contributed to higher insurance premiums in 2026. The administration has criticized those subsidies as benefiting insurers at the expense of patients and has promoted the Great Healthcare Plan to redirect support directly to individuals.

Trump has repeatedly highlighted the contrast with prior policies, noting that Americans previously paid nearly three times more for medicines than patients in comparable nations. The new agreements extend the most-favored-nation approach already applied to 17 major drugmakers covering about 86 percent of the branded market.

White House officials said the latest pacts continue the focus on transparency and direct patient savings without expanding government subsidies to insurance companies.